China has been experiencing violent protests against COVID restrictions while U.S. cases have been rising. The violence comes after China reported 2,230 new cases in the southern manufacturing and technology hub of Guangzhou, and at a time when an increasing number of reports say the government is considering steps to ease the zero-COVID policy. (MarketWatch)

Hexagon Bio, a SoftBank-backed biotech, raised additional funds after bagging more than $100 million for fungi mining. An SEC filing details the total offering could eventually go beyond that figure, to almost $80 million. The first sale in the Menlo Park, CA, biotech’s offering was Sept. 30. (Endpoints News)

Glenmark Pharmaceuticals Inc. USA and other generic drugmakers beat appeal in a union’s suit over generic Zantac. The U.S. Court of Appeals for the Eleventh Circuit said the union’s failure to contest the dismissal of the suit as a “shotgun pleading” doomed the challenge in an unpublished per curiam order. (Bloomberg)

Aurobindo units recalled products in the U.S. for manufacturing issues. The medication is used to treat high blood pressure. Per the USFDA, the company is recalling the affected lot due to “Current good manufacturing practices CGMP deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.” (The Economic Times)

Royalty Pharma reported its Q3 results Tuesday and raised its full-year guidance. The company’s adjusted cash receipts are expected to be $2.75 billion to $2.8 billion, which includes $458 million from the acceleration of payments related to Pfizer’s acquisition of Biohaven. (Seeking Alpha)